Press Releases

July 15, 2019 at 7:00 AM EDT
Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc.
GAITHERSBURG, Md. , July 15, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of Spitfire Pharma, Inc. , including the product candidate ALT-801, a potent GLP-1/Glucagon receptor
June 12, 2019 at 8:00 AM EDT
Altimmune Appoints Will Brown as Chief Financial Officer
GAITHERSBURG, Md. , June 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed Will Brown as Chief Financial Officer. Mr. Brown has been serving as the Acting Chief Financial Officer since May 2018 .
June 10, 2019 at 8:00 AM EDT
Altimmune Announces Successful Pre-IND Meeting with FDA
Meeting on HepTcell Phase 2 program for treatment of chronic hepatitis B (HBV) GAITHERSBURG, Md. , June 10, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it successfully completed a pre-IND (Investigational New Drug) meeting
May 8, 2019 at 8:00 AM EDT
Altimmune to Announce First Quarter 2019 Financial Results on May 15
GAITHERSBURG, Md. , May 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March 31, 2019 before the market open and host a conference call on Wednesday, May 15,
March 21, 2019 at 4:15 PM EDT
Altimmune to Announce Year End 2018 Financial Results on April 2
GAITHERSBURG, Md. , March 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the year ended December 31, 2018 before the market open and host a conference call on Tuesday, April 2, 2019
Displaying 1 - 10 of 15

Investor Contact

Ashley Robinson
LifeSci Advisors, LLC

Email: arr@lifesciadvisors.com

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe